Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 297 entries
Sorted by: Best Match Show Resources per page
Adult Acute Myeloid Leukemia Long-term Survivors.

Journal of leukemia (Los Angeles, Calif.)

Cheng MJ, Hourigan CS, Smith TJ.
PMID: 25243197
J Leuk (Los Angel). 2014 Apr 10;2(2). doi: 10.4172/2329-6917.1000135.

The number of leukemia patients and survivors is growing. This review summarizes what is known regarding the health related quality of life (HRQOL) and medical complications associated with acute myeloid leukemia (AML) disease and treatment and highlights understudied aspects...

Cite
Cheng MJ, Hourigan CS, Smith TJ. Adult Acute Myeloid Leukemia Long-term Survivors. J Leuk (Los Angel). 2014;2(2)doi: 10.4172/2329-6917.1000135.
Cheng, M. J., Hourigan, C. S., & Smith, T. J. (2014). Adult Acute Myeloid Leukemia Long-term Survivors. Journal of leukemia (Los Angeles, Calif.), 2(2), . https://doi.org/10.4172/2329-6917.1000135
Cheng, M Jennifer, et al. "Adult Acute Myeloid Leukemia Long-term Survivors." Journal of leukemia (Los Angeles, Calif.) vol. 2,2 (2014). doi: https://doi.org/10.4172/2329-6917.1000135
Cheng MJ, Hourigan CS, Smith TJ. Adult Acute Myeloid Leukemia Long-term Survivors. J Leuk (Los Angel). 2014 Apr 10;2(2). doi: 10.4172/2329-6917.1000135. PMID: 25243197; PMCID: PMC4167020.
Copy Download .nbib Format: NLM
[No title available]

Oncotarget

Pankov D, Sjöström L, Kalidindi T, Lee SG, Sjöström K, Gardner R, McDevitt MR, O'Reilly R, Thorek DLJ, Larson SM, Veach D, Ulmert D.
PMID: 29029482
Oncotarget. 2017 Jul 26;8(39):65917-65931. doi: 10.18632/oncotarget.19579. eCollection 2017 Sep 12.

Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is overexpressed in a broad range of malignancies, while absent in most healthy human tissues, making it an attractive diagnostic cancer biomarker and therapeutic target. Although commonly viewed...

Cite
Pankov D, Sjöström L, Kalidindi T, et al. . Oncotarget. 2017;8(39):65917-65931doi: 10.18632/oncotarget.19579.
Pankov, D., Sjöström, L., Kalidindi, T., Lee, S. G., Sjöström, K., Gardner, R., McDevitt, M. R., O'Reilly, R., Thorek, D. L. J., Larson, S. M., Veach, D., & Ulmert, D. (2017). . Oncotarget, 8(39), 65917-65931. https://doi.org/10.18632/oncotarget.19579
Pankov, Dmitry, et al. "." Oncotarget vol. 8,39 (2017): 65917-65931. doi: https://doi.org/10.18632/oncotarget.19579
Pankov D, Sjöström L, Kalidindi T, Lee SG, Sjöström K, Gardner R, McDevitt MR, O'Reilly R, Thorek DLJ, Larson SM, Veach D, Ulmert D. . Oncotarget. 2017 Jul 26;8(39):65917-65931. doi: 10.18632/oncotarget.19579. eCollection 2017 Sep 12. PMID: 29029482; PMCID: PMC5630382.
Copy Download .nbib Format: NLM
A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain.

Case reports in oncological medicine

Ruzevick J, Nicholas S, Redmond K, Kleinberg L, Lipson EJ, Lim M.
PMID: 24383025
Case Rep Oncol Med. 2013;2013:946392. doi: 10.1155/2013/946392. Epub 2013 Dec 08.

Cancers, such as melanoma, that are associated with immune deficiencies are a major cause of morbidity and mortality in HIV-infected patients. Once patients develop melanoma metastases to the brain, treatment is often limited to palliative surgery and/or radiation. Ipilimumab,...

Cite
Ruzevick J, Nicholas S, Redmond K, et al. A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain. Case Rep Oncol Med. 2013;2013:946392doi: 10.1155/2013/946392.
Ruzevick, J., Nicholas, S., Redmond, K., Kleinberg, L., Lipson, E. J., & Lim, M. (2013). A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain. Case reports in oncological medicine, 2013946392. https://doi.org/10.1155/2013/946392
Ruzevick, Jacob, et al. "A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain." Case reports in oncological medicine vol. 2013 (2013): 946392. doi: https://doi.org/10.1155/2013/946392
Ruzevick J, Nicholas S, Redmond K, Kleinberg L, Lipson EJ, Lim M. A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain. Case Rep Oncol Med. 2013;2013:946392. doi: 10.1155/2013/946392. Epub 2013 Dec 08. PMID: 24383025; PMCID: PMC3870634.
Copy Download .nbib Format: NLM
Molecular heterogeneity of localized prostate cancer: more different than alike.

Translational cancer research

Tosoian JJ, Antonarakis ES.
PMID: 28529909
Transl Cancer Res. 2017 Feb;6:S47-S50. doi: 10.21037/tcr.2017.02.17.

No abstract available.

Cite
Tosoian JJ, Antonarakis ES. Molecular heterogeneity of localized prostate cancer: more different than alike. Transl Cancer Res. 2017;6:S47-S50doi: 10.21037/tcr.2017.02.17.
Tosoian, J. J., & Antonarakis, E. S. (2017). Molecular heterogeneity of localized prostate cancer: more different than alike. Translational cancer research, 6S47-S50. https://doi.org/10.21037/tcr.2017.02.17
Tosoian, Jeffrey J, and Antonarakis, Emmanuel S. "Molecular heterogeneity of localized prostate cancer: more different than alike." Translational cancer research vol. 6 (2017): S47-S50. doi: https://doi.org/10.21037/tcr.2017.02.17
Tosoian JJ, Antonarakis ES. Molecular heterogeneity of localized prostate cancer: more different than alike. Transl Cancer Res. 2017 Feb;6:S47-S50. doi: 10.21037/tcr.2017.02.17. PMID: 28529909; PMCID: PMC5438201.
Copy Download .nbib Format: NLM
Practice gaps and barriers to optimal care of hematologic malignancies in the United States.

The Journal of community and supportive oncology

Murray S, Obholz KL, Bowser AD, Mortimer J, Lazure P, Peterson E, Armitage JO, Smith BD.
PMID: 25811037
J Community Support Oncol. 2014 Sep;12(9):329-338. doi: 10.12788/jcso.0073.

BACKGROUND: Treating patients with hematologic malignancies can be challenging for physicians because of the rapidly evolving standards of care and relatively low incidence of these diseases.OBJECTIVE: To identify clinical challenges among hematologists and medical oncologists regarding the provision of...

Cite
Murray S, Obholz KL, Bowser AD, et al. Practice gaps and barriers to optimal care of hematologic malignancies in the United States. J Community Support Oncol. 2014;12(9):329-338doi: 10.12788/jcso.0073.
Murray, S., Obholz, K. L., Bowser, A. D., Mortimer, J., Lazure, P., Peterson, E., Armitage, J. O., & Smith, B. D. (2014). Practice gaps and barriers to optimal care of hematologic malignancies in the United States. The Journal of community and supportive oncology, 12(9), 329-338. https://doi.org/10.12788/jcso.0073
Murray, Suzanne, et al. "Practice gaps and barriers to optimal care of hematologic malignancies in the United States." The Journal of community and supportive oncology vol. 12,9 (2014): 329-338. doi: https://doi.org/10.12788/jcso.0073
Murray S, Obholz KL, Bowser AD, Mortimer J, Lazure P, Peterson E, Armitage JO, Smith BD. Practice gaps and barriers to optimal care of hematologic malignancies in the United States. J Community Support Oncol. 2014 Sep;12(9):329-338. doi: 10.12788/jcso.0073. PMID: 25811037; PMCID: PMC4370227.
Copy Download .nbib Format: NLM
Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids.

Cancer cell

Nelson WG, Haffner MC, Yegnasubramanian S.
PMID: 21741594
Cancer Cell. 2011 Jul 12;20(1):7-9. doi: 10.1016/j.ccr.2011.06.019.

In the May 26th issue of the New England Journal of Medicine, de Bono et al. report that the inhibition of androgen synthesis by abiraterone acetate prolonged the survival of men with prostate cancer previously treated by androgen suppression.

Cite
Nelson WG, Haffner MC, Yegnasubramanian S. Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids. Cancer Cell. 2011;20(1):7-9doi: 10.1016/j.ccr.2011.06.019.
Nelson, W. G., Haffner, M. C., & Yegnasubramanian, S. (2011). Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids. Cancer cell, 20(1), 7-9. https://doi.org/10.1016/j.ccr.2011.06.019
Nelson, William G, et al. "Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids." Cancer cell vol. 20,1 (2011): 7-9. doi: https://doi.org/10.1016/j.ccr.2011.06.019
Nelson WG, Haffner MC, Yegnasubramanian S. Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids. Cancer Cell. 2011 Jul 12;20(1):7-9. doi: 10.1016/j.ccr.2011.06.019. PMID: 21741594; PMCID: PMC4479125.
Copy Download .nbib Format: NLM
Implications of systemic dysfunction for the etiology of malignancy.

Gene regulation and systems biology

Knox SS, Ochs MF.
PMID: 23440603
Gene Regul Syst Bio. 2013;7:11-22. doi: 10.4137/GRSB.S10943. Epub 2013 Feb 06.

The current approach to treatment in oncology is to replace the generally cytotoxic chemotherapies with pharmaceutical treatment which inactivates specific molecular targets associated with cancer development and progression. The goal is to limit cellular damage to pathways perceived to...

Cite
Knox SS, Ochs MF. Implications of systemic dysfunction for the etiology of malignancy. Gene Regul Syst Bio. 2013;7:11-22doi: 10.4137/GRSB.S10943.
Knox, S. S., & Ochs, M. F. (2013). Implications of systemic dysfunction for the etiology of malignancy. Gene regulation and systems biology, 711-22. https://doi.org/10.4137/GRSB.S10943
Knox, Sarah S, and Ochs, Michael F. "Implications of systemic dysfunction for the etiology of malignancy." Gene regulation and systems biology vol. 7 (2013): 11-22. doi: https://doi.org/10.4137/GRSB.S10943
Knox SS, Ochs MF. Implications of systemic dysfunction for the etiology of malignancy. Gene Regul Syst Bio. 2013;7:11-22. doi: 10.4137/GRSB.S10943. Epub 2013 Feb 06. PMID: 23440603; PMCID: PMC3572920.
Copy Download .nbib Format: NLM
Infection of Xenotransplanted Human Cell Lines by Murine Retroviruses: A Lesson Brought Back to Light by XMRV.

Frontiers in oncology

Hempel HA, Burns KH, De Marzo AM, Sfanos KS.
PMID: 23785669
Front Oncol. 2013 Jun 17;3:156. doi: 10.3389/fonc.2013.00156. eCollection 2013.

Infection of xenotransplanted human cells by xenotropic retroviruses is a known phenomenon in the scientific literature, with examples cited since the early 1970s. However, arguably, until recently, the importance of this phenomenon had not been largely recognized. The emergence...

Cite
Hempel HA, Burns KH, De Marzo AM, et al. Infection of Xenotransplanted Human Cell Lines by Murine Retroviruses: A Lesson Brought Back to Light by XMRV. Front Oncol. 2013;3:156doi: 10.3389/fonc.2013.00156.
Hempel, H. A., Burns, K. H., De Marzo, A. M., & Sfanos, K. S. (2013). Infection of Xenotransplanted Human Cell Lines by Murine Retroviruses: A Lesson Brought Back to Light by XMRV. Frontiers in oncology, 3156. https://doi.org/10.3389/fonc.2013.00156
Hempel, Heidi A, et al. "Infection of Xenotransplanted Human Cell Lines by Murine Retroviruses: A Lesson Brought Back to Light by XMRV." Frontiers in oncology vol. 3 (2013): 156. doi: https://doi.org/10.3389/fonc.2013.00156
Hempel HA, Burns KH, De Marzo AM, Sfanos KS. Infection of Xenotransplanted Human Cell Lines by Murine Retroviruses: A Lesson Brought Back to Light by XMRV. Front Oncol. 2013 Jun 17;3:156. doi: 10.3389/fonc.2013.00156. eCollection 2013. PMID: 23785669; PMCID: PMC3683812.
Copy Download .nbib Format: NLM
Infections and inflammation in prostate cancer.

American journal of clinical and experimental urology

Sfanos KS, Isaacs WB, De Marzo AM.
PMID: 25110720
Am J Clin Exp Urol. 2013 Dec 25;1(1):3-11.

The frequent observation of both acute and chronic inflammation of unknown stimulus in the adult prostate has motivated a large body of research aimed at identifying potential infectious agents that may elicit prostatic inflammation. The overarching hypothesis is that...

Cite
Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. Am J Clin Exp Urol. 2013;1(1):3-11
Sfanos, K. S., Isaacs, W. B., & De Marzo, A. M. (2013). Infections and inflammation in prostate cancer. American journal of clinical and experimental urology, 1(1), 3-11.
Sfanos, Karen S, et al. "Infections and inflammation in prostate cancer." American journal of clinical and experimental urology vol. 1,1 (2013): 3-11.
Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. Am J Clin Exp Urol. 2013 Dec 25;1(1):3-11. PMID: 25110720; PMCID: PMC4219279.
Copy Download .nbib Format: NLM
[No title available]

Oncotarget

Gustin JP, Miller J, Farag M, Rosen DM, Thomas M, Scharpf RB, Lauring J.
PMID: 29262572
Oncotarget. 2017 Oct 20;8(61):103415-103427. doi: 10.18632/oncotarget.21910. eCollection 2017 Nov 28.

The

Cite
Gustin JP, Miller J, Farag M, et al. . Oncotarget. 2017;8(61):103415-103427doi: 10.18632/oncotarget.21910.
Gustin, J. P., Miller, J., Farag, M., Rosen, D. M., Thomas, M., Scharpf, R. B., & Lauring, J. (2017). . Oncotarget, 8(61), 103415-103427. https://doi.org/10.18632/oncotarget.21910
Gustin, John P, et al. "." Oncotarget vol. 8,61 (2017): 103415-103427. doi: https://doi.org/10.18632/oncotarget.21910
Gustin JP, Miller J, Farag M, Rosen DM, Thomas M, Scharpf RB, Lauring J. . Oncotarget. 2017 Oct 20;8(61):103415-103427. doi: 10.18632/oncotarget.21910. eCollection 2017 Nov 28. PMID: 29262572; PMCID: PMC5732738.
Copy Download .nbib Format: NLM
Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.

Oncotarget

Nagai K, Hou L, Li L, Nguyen B, Seale T, Shirley C, Ma H, Levis M, Ghiaur G, Duffield A, Small D.
PMID: 30250637
Oncotarget. 2018 Aug 31;9(68):32885-32899. doi: 10.18632/oncotarget.25972. eCollection 2018 Aug 31.

Acute myeloid leukemia (AML) patients with FLT3/ITD mutations have a poor prognosis. Monotherapy with selective FLT3 tyrosine kinase inhibitors (TKIs) have shown transient and limited efficacy due to the development of resistance. Arsenic trioxide (ATO, As

Cite
Nagai K, Hou L, Li L, et al. Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget. 2018;9(68):32885-32899doi: 10.18632/oncotarget.25972.
Nagai, K., Hou, L., Li, L., Nguyen, B., Seale, T., Shirley, C., Ma, H., Levis, M., Ghiaur, G., Duffield, A., & Small, D. (2018). Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget, 9(68), 32885-32899. https://doi.org/10.18632/oncotarget.25972
Nagai, Kozo, et al. "Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3." Oncotarget vol. 9,68 (2018): 32885-32899. doi: https://doi.org/10.18632/oncotarget.25972
Nagai K, Hou L, Li L, Nguyen B, Seale T, Shirley C, Ma H, Levis M, Ghiaur G, Duffield A, Small D. Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget. 2018 Aug 31;9(68):32885-32899. doi: 10.18632/oncotarget.25972. eCollection 2018 Aug 31. PMID: 30250637; PMCID: PMC6152471.
Copy Download .nbib Format: NLM
AR-V7 and treatment selection in advanced prostate cancer: are we there yet?.

Precision cancer medicine

Bastos DA, Antonarakis ES.
PMID: 30370427
Precis Cancer Med. 2018 Sep;1. doi: 10.21037/pcm.2018.09.01. Epub 2018 Sep 18.

No abstract available.

Cite
Bastos DA, Antonarakis ES. AR-V7 and treatment selection in advanced prostate cancer: are we there yet?. Precis Cancer Med. 2018;1doi: 10.21037/pcm.2018.09.01.
Bastos, D. A., & Antonarakis, E. S. (2018). AR-V7 and treatment selection in advanced prostate cancer: are we there yet?. Precision cancer medicine, 1. https://doi.org/10.21037/pcm.2018.09.01
Bastos, Diogo A, and Antonarakis, Emmanuel S. "AR-V7 and treatment selection in advanced prostate cancer: are we there yet?." Precision cancer medicine vol. 1 (2018). doi: https://doi.org/10.21037/pcm.2018.09.01
Bastos DA, Antonarakis ES. AR-V7 and treatment selection in advanced prostate cancer: are we there yet?. Precis Cancer Med. 2018 Sep;1. doi: 10.21037/pcm.2018.09.01. Epub 2018 Sep 18. PMID: 30370427; PMCID: PMC6201248.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 297 entries